WP
CUE icon

Woodline Partners’s Cue Biopharma CUE Stock Holding History

Woodline Partners’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-9,504
Closed -$4.15M – 718
2021
Q3 		$4.15M Sell
9,504
-12,737
-57% -$4.44M 0.07% 282
2021
Q2 		$7.77M Buy
22,241
+15,481
+229% +$6M 0.15% 168
2021
Q1 		$2.47M Sell
6,760
-10,243
-60% -$4.22M 0.05% 269
2020
Q4 		$6.38M Sell
17,003
-13,486
-44% -$5.39M 0.17% 147
2020
Q3 		$13.8M Buy
30,489
+8,509
+39% +$4.9M 0.45% 64
2020
Q2 		$16.2M Buy
+21,980
New +$15.9M 0.64% 52

Other funds holding CUE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

Woodline Partners's CUE Position: Q4 2021 in Review

Woodline Partners sold out of Cue Biopharma (CUE) in Q4 2021, closing a stake of 9,504 shares — an estimated $4.15M sold.

Woodline Partners first reported a position in CUE in Q2 2020 and held it in 6 quarters. The position peaked at $16.2M in Q2 2020. 90 funds tracked by Wall St. Rank hold CUE as of Q4 2021.

  • Woodline Partners reported no remaining Cue Biopharma position as of Q4 2021 after selling out during the quarter.
  • Woodline Partners sold 9,504 Cue Biopharma shares in Q4 2021, an estimated $4.15M.
  • Woodline Partners first reported a position in Cue Biopharma in Q2 2020 and held it in 6 quarters.
  • Woodline Partners's Cue Biopharma position peaked at $16.2M in Q2 2020.
  • 90 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2021.

Based on Woodline Partners's 13F filing for Q4 2021, filed 14 Feb 2022.